Beauty Health CO 8-K filings

SkinHealth Systems Inc. announced the resignation of its Chief Operations, Quality and Technology Officer, Sheri Lewis, effective August 28, 2026.

SkinHealth Systems Inc. announced the results of its annual meeting of stockholders held on June 10, 2026, including the election of nine directors and the ratification of its independent auditor.

SkinHealth Systems Inc. files an amendment to its Form 8-K to disclose the details of a severance agreement with former Chief Revenue Officer, Ronald Menezes.

SkinHealth Systems Inc. received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, with 180 days to regain compliance.

SkinHealth Systems Inc. announced the termination of Chief Revenue Officer Ronald Menezes without cause, effective May 5, 2026, with separation agreement details pending.

The Beauty Health Company announced its corporate rebrand to SkinHealth Systems Inc., effective immediately, signaling a strategic shift towards a clinically driven, science-backed medical aesthetics platform, alongside the appointment of three new independent directors to its Board.

BeautyHealth reported improved margins and profitability in the fourth quarter and full year 2025, despite a decrease in overall net sales.

The Beauty Health Company has reached a proposed settlement in a consolidated stockholder derivative action, agreeing to implement significant corporate governance reforms.

The Beauty Health Company reported third-quarter 2025 financial results, with revenue of $70.7 million and Adjusted EBITDA of $8.9 million exceeding guidance, despite a decline in device sales.

The Beauty Health Company announced the appointment of Dr. Philippe Schaison, a global aesthetics leader, to its Board of Directors, effective October 30, 2025.

The Beauty Health Company filed an amendment to its 8-K, detailing the severance and consulting agreement for former CEO Marla Beck, who departed effective September 30, 2025.

The Beauty Health Company announces Pedro Malha as its new President and CEO, effective October 1, 2025, succeeding Marla Beck.

The Beauty Health Company has enhanced the security of its 7.95% Convertible Senior Secured Notes due 2028 by adding its UK and German subsidiaries as guarantors.

BeautyHealth reported strong second-quarter 2025 financial results, exceeding revenue and Adjusted EBITDA expectations, driven by consumables sales and improved gross margins, leading to an increased full-year outlook.

The Beauty Health Company filed a Certificate of Correction to its corporate bylaws, clarifying director removal provisions, and appointed Stephen Fanning as Chairman of the Nominating and Corporate Governance Committee.

The Beauty Health Company held its annual meeting on June 12, 2025, with stockholders electing seven directors, ratifying Deloitte & Touche LLP as its independent auditor, and approving executive compensation on an advisory basis.

The Beauty Health Company has issued $250 million in 7.95% Convertible Senior Secured Notes due 2028, enhancing its capital structure with a first-priority secured debt instrument.

Beauty Health refinances convertible debt, extending maturity and strengthening financial position for growth.

The Beauty Health Company reports a decrease in Q1 2025 revenue due to lower delivery system sales, but demonstrates improved gross margins and adjusted EBITDA.

BeautyHealth announces Q4 and full year 2024 financial results, exceeding net sales and adjusted EBITDA guidance despite macroeconomic headwinds.

The Beauty Health Company designates Ronald Menezes as an executive officer and Section 16 Officer, and Sheri Lewis as an executive officer and Section 16 Officer, reflecting the expanded scope of their roles.

The Beauty Health Company has appointed medical aesthetics veteran Stephen J. Fanning to its Board of Directors, effective December 12, 2024.

The Beauty Health Company reported a decrease in third-quarter revenue but showed improved profitability driven by strategic initiatives and cost management.

The Beauty Health Company has announced the termination of its Chief Revenue Officer, Daniel Watson, effective October 14, 2024, and has entered into a separation agreement with him.

The Beauty Health Company has terminated its Chief Revenue Officer, Daniel Watson, effective October 14, 2024, with him transitioning to an advisory role until December 31, 2024.

Dr. Julius Few has resigned from the board of directors of The Beauty Health Company, effective August 26, 2024.

The Beauty Health Company reported a 22.9% decrease in net sales for the second quarter of 2024, driven by lower equipment sales, and has revised its full-year financial guidance.

The Beauty Health Company's shareholders approved amendments to declassify the board of directors and eliminate the supermajority voting requirement at the 2024 annual meeting.

The Beauty Health Company reported a 5.7% decrease in net sales for the first quarter of 2024, but improved profitability through cost management and debt repurchases.

The Beauty Health Company's Chief Operating Officer, Brad Hauser, has mutually terminated his employment, effective April 9, 2024, and will transition to an advisory role until no later than June 30, 2024, with a separation package including $400,000 in severance pay.